migraine – media

Connection between Anxiety, Depression and Migraine Studied by Novartis & Healint with Self Tracking App

A new study conducted by Novartis and Healint using Migraine Buddy, Healint’s migraine tracking app. Proved that, contrary to earlier belief, long-standing migraines could engender anxiety and depression.
- Source: Ddu
- 750
- September 3, 2018
anxiety Depression Mental health migraine Researches
Electrocore Releases Gammacore Therapy against Migraine and Episodic Cluster Headaches

ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.
- Source: FierceBiotech
- 784
- July 19, 2018
biotech cluster headache medtech migraine New Approvals
Aimovig a New Drug for Migraines Gets Approval from FDA

Aimovig, a ground-breaking drug to prevent Migraines was approved by the FDA last week. Aimovig will be the only player in the market to treat migraines. The new drug has to be taken once a month through an injection similar to an insulin shot or an EpiPen.
- Source: Ddu
- 657
- May 21, 2018
FDA migraine New Approvals
Study reveals combination of various genetic factors influence migraine risks

An investigation on 2 different theories about the hereditary ways in which migraines are found in family lines was conducted by a transatlantic team.
- Source: Ddu
- 609
- May 7, 2018
migraine Researches
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures

The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meeting
- Source: prnewswire
- 650
- April 20, 2018
Amgen migraine
XOC PHARMACEUTICALS ANNOUNCES $30 MILLION SERIES A FINANCING LED BY NEA

Company to move forward with novel therapies for migraine and Parkinson’s disease
- Source: xocpharma
- 558
- February 27, 2018
CNS migraine Parkinson’s disease Series
New study links migraines to increased risk of cardiovascular problems

© Provided by AFPRelaxNews Migraine sufferers could be at an increased risk of certain heart problems according to new research.New international research has found that migraine sufferers may also have an increased risk of cardiovascular problems including heart attacks, stroke, blood clots, and an irregular heart rate.
- Source: msn
- 657
- February 8, 2018
cardiovascular migraine Researches
Amgen Jumps as Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
- Source: biospace
- 632
- January 25, 2018
Aimovig Amgen Clinical Trials episodic headaches migraine
FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. Additionally, the FDA has granted fast track designation for fremanezumab for the prevention of cluster headache.
- Source: finance.yahoo
- 583
- December 19, 2017
cluster headache FDA fremanezumab migraine New Approvals Teva

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.